If both tumor and matched blood have been sequenced, this distinction can be informed by variations in VAF of the clone between the two samples, with higher blood VAF indicating a clone of hematopoietic origin.40 With tumor-only sequencing, CH mutations may lead to incorrect reporting of tumor variants, potentially leading to recommendations for inappropriate targeted therapies of little to no clinical benefit. This evidence concerns the gene C4B and neoplasm.